Abstract
Introduction: S100B is a neurotrophic factor that regulates neuronal growth and plasticity by activating astrocytes and microglia. This process produces neuro-inflammatory molecules like interleukin (IL)-1β, which are involved in various mental disorders. Few studies have combined S100B and cytokines to explore their roles as neuro-inflammatory biomarkers in Generalized Anxiety Disorder (GAD). Methods: Serum S100B and cytokines (IL-1β, IL-2, IL-4, and IL-10) of 108 untreated GAD cases and 123 healthy controls (HC) were determined by enzyme-linked immunosorbent assay (ELISA). Hamilton Anxiety Rating Scale (HAMA) scores were used to evaluate anxiety severity. Results: Serum S100B, IL-1β, and IL-2 levels were significantly lower in GAD cases than in HC (P < 0.001). IL-4 levels were higher in GAD (P < 0.001), while IL-10 showed no significant difference. The combined ROC area for S100B, IL-1β, IL-2, and IL-4 was 0.985 ± 0.006 (P < 0.001). Serum S100B was negatively correlated with HAMA scores (P < 0.001). Conclusion: The down-regulation of S100B, IL-1β, and IL-2, alongside the up-regulation of IL-4, suggests a complex neuro-inflammatory network in GAD. A combined biomarker panel offers superior diagnostic value.
Introduction
Generalized Anxiety Disorder (GAD) is a chronic psychiatric condition characterized by persistent and excessive worry. Despite its prevalence, GAD remains difficult to diagnose objectively, relying heavily on clinical interviews and subjective symptom reporting. There is a critical need for "gold standard" laboratory tests to improve diagnostic accuracy.
Recent research suggests that chronic neuroinflammation—the brain's immune response—plays a significant role in anxiety. This study investigates whether S100B, a protein involved in neuronal plasticity, and various cytokines (immune signaling molecules) can serve as reliable biological markers to distinguish GAD patients from healthy individuals.
Methods
The researchers conducted a case-control study involving 231 participants recruited from Huzhou Third Municipal Hospital in China. The cohort consisted of 108 untreated GAD patients (Han nationality, aged 18-65, drug-free for at least four weeks) and 123 age- and sex-matched healthy controls.
Key technical aspects included:
- Clinical Assessment: Anxiety severity was measured using the Hamilton Anxiety Rating Scale (HAMA).
- Biochemical Analysis: Serum levels of S100B and four cytokines (IL-1β, IL-2, IL-4, and IL-10) were determined using ELISA kits.
- Statistical Modeling: Receiver Operating Characteristic (ROC) curves were utilized to evaluate the diagnostic power of these markers, both individually and in combination.
Results
Biomarker Comparison
The study found significant differences in the serum profiles of GAD patients compared to healthy controls. Notably, GAD patients exhibited significantly lower levels of S100B, IL-1β, and IL-2. Conversely, IL-4, an anti-inflammatory cytokine, was significantly higher in the GAD group, potentially indicating a compensatory immune response.
Diagnostic Performance
Individual markers demonstrated strong diagnostic potential. The ROC area (AUC) for IL-1β and IL-2 were particularly high at 0.900 and 0.920, respectively. However, the most significant finding was the synergy of the combined panel (S100B, IL-1β, IL-2, and IL-4), which achieved an AUC of 0.985, indicating excellent diagnostic accuracy.
Discussion
The finding that S100B, IL-1β, and IL-2 levels were lower in GAD patients supports the "decompensation" hypothesis. While S100B often increases during acute stress to act as a protective factor, chronic GAD may lead to system exhaustion, resulting in the observed down-regulation. This is further supported by the negative correlation between S100B levels and HAMA scores: lower S100B levels were associated with more severe anxiety symptoms.
Conclusion
This study identifies a potential "biomarker signature" for GAD. While individual markers like IL-2 show high sensitivity, the combination of S100B and specific cytokines provides a much clearer diagnostic picture. This suggests that neuroinflammation in GAD is a complex network regulated by multiple factors. Future research should focus on larger, more diverse cohorts and longitudinal designs to determine if these markers normalize following successful treatment.
Summary updated